Abstract
Ranibizumab (Lucentis®, Genentech, Novartis) is a recombinant humanized IgG1k monoclonal Fab fragment binding to human vascular endothelial growth factor-A (VEGF-A). In June 2006, FDA approved ranibizumab for intravitreal (IVI) treatment of neovascular age-related (wet) macular degeneration (AMD). In March 2007, EMEA granted approval for the same indication. In June 2010, on the basis of additional data, FDA extended the indication to macular edema following retinal vein occlusion (RVO), and in October 2012 to the treatment of patients with diabetic macular edema (DME).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ranibizumab (Lucentis®) BLA125156 Medical Review FDA, June 2006
Ranibizumab (Lucentis®) WC500043550 Scientific Discussion EMEA Mar 2007
Ranibizumab (Lucentis®) WC500043546 EPAR Annex I, EMEA Aug 2009
Ranibizumab (Lucentis®) WC5000101009 Assessment Report ranibizumab (AMD) WC5000101009 EMEA Assessment Report (DME), Oct 2010
Ranibizumab (Lucentis®) WC5000107807 EMEA Assessment Report (RVO), Mar 2011
Ranibizumab (Lucentis®) AusPAR for ranibizumab, ARTG: 125968, 148325, TGA, Nov 2011
Ranibizumab (Lucentis®) Prescribing Information, Genentech, Aug 2012
Cruess AF, Berger A, Colleaux K et al (2012) Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Can J Ophthalmol 47:227–235
Carmelier P and Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: doi:10.1038/nature10144
Chang J-H, Garg NK, Lunde E et al (2012) Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 57:415–429
DeNiro M, Al-Mohanna F (2011) Reversal of retinal vascular changes associated with ocular neovascularization by small molecules: progress toward identifying molecular targets for therapeutic intervention. Open Diabetes J 4:75–95
Parmeggiani F, Romano MR, Costagliola C et al (2012) Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm. doi:10.1155/2012/546786
Costagliola C, Agnifili L, Arcidiacono B et al (2012) Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 12:1299–1313
Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 67:77–88
Finger RP, Wiedemann P, Blumhagen F et al (2012) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study—A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. doi:10.1111/j.1755-3768.2012.02493.x
Silva R, Axer-Siegel R, Eldem B et al (2012) The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. doi:10.1016/j.ophtha.2012.07.026
Chen Y, Han F (2012) Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Therap Clin Risk Manag 8:343–351
Singer MA, Awh CC, Sadda SV et al (2012) HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119:1175–1183
Bressler NM, Boyer DS, Williams DF et al (2012) Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 32:1821–1828
Ho AC, Scott IU, Kim SJ et al (2012) Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema. Ophthalmology 119:2179–2188
Ford J, Elders A, Shyangdan D et al (2012) The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular edema: an indirect comparison in a systematic review. BMJ 345:e5182
Fung AE, Rosenfeld PJ, Reichel E et al (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349
Wang H, Sun X, Liu K et al (2012) Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res 37:661–670
Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for macular oedema following BRVO: six-month primary end point results of a phase 3 study. Ophthalmology 117:1102–1112
Varma R, Bressler NM, Suñer I et al (2012) Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion. Results from the BRAVO and CRUISE trials. Ophthalmology 119:2108–2118
Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 119:1388–1398
Sharma S, Johnson D, Abouammoh M et al (2012) Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 47:275–279
Carneiro AM, Mendonça LS, Falcão MS et al (2012) Comparative study of I + PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol 6:1149–1157
Chakravarthi U, Harding SP, Rogers CA et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
Schumcker C, Ehlken C, Agostini HT et al (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 7:e42701
Wehrli SJ, Tawse K, Levin MH et al (2012) A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 32:1295–1301
Yeh S, Albini TA, Moshfeghi A et al (2012) Uveitis, the comparison of age-related macular degeneration treatments trials (CATT), and intravitreal biologics of ocular inflammation. Am J Ophthalmol 154:429–435
Fernandez M, Gil M, Gomez-Ulla F et al (2012) Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Controversy concerning long-term followup. Case Rep Med doi:10.1155/2012/897097
Nemoto R, Miura M, Iwasaki T et al (2012) Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Clin Ophthalmol 6:1633–1638
Saito M, Iida T and Kano M (2012) Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol doi: 10.1007/s10384-012-0215-7
Marcus Dm, Singh H, Lott MN et al (2012) Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients. Retina 0:1–13
Iacono P, Battaglia Parodi M, Papayannis A et al (2012) Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 32:1539–1546
Zebardast N, Adelman RA (2012) Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum: five-year follow-up. Semin Ophthalmol 27:61–64
Campbell RJ, Gill SS, Bronskill SE et al (2012) Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case control studies. BMJ 345:e4203. doi:10.1136/bmj.e4203
Ehlken C, Martin G, Stahl A et al (2012) Reduction of endothelial growth factor A in human breast milk after intravitreal injection of bevacizumab but not ranibizumab. Arch Ophthalmol 130:1226–1227
Martinez de la Casa JM, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214–6218
Nishimura T, Machida S, Harada T et al (2012) Retinal ganglion cell function repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol 6:1073–1082
Elman MJ, Qin H, Aiello LP et al (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment. Ophthalmology 119:2312–2318
Fung AT, Kumar N, Vance SK et al (2012) Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST study) Eye 26:1181–1187
Jutley G, Shona OA, Cheong Leen R et al (2012) Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol 130:1466–1470
Wu WK, Liewellyn OP, Bates DO et al (2010) IL-10 regulation of macrophage VEGF production is dependent on macrophage polarization and hypoxia. Immunobiology 215:796–803
Kaiser PK, Cruess AF, Bogaert P et al (2012) Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risk associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 250:1563–1571
Author information
Authors and Affiliations
Corresponding author
1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Ranibizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_34
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_34
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)